-
Je něco špatně v tomto záznamu ?
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
JW. van Straalen, RM. Krol, G. Giancane, V. Panaviene, LM. Ailioaie, P. Doležalová, M. Cattalini, G. Susic, FR. Sztajnbok, D. Maritsi, T. Constantin, S. Sawhney, M. Rygg, SK. Oliveira, EB. Nordal, C. Saad-Magalhães, N. Rubio-Perez, M. Jelusic, S....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
Medline Complete (EBSCOhost)
od 1999-01-01 do Před 1 rokem
- MeSH
- antirevmatika * škodlivé účinky MeSH
- dítě MeSH
- etanercept škodlivé účinky MeSH
- idiopatické střevní záněty * farmakoterapie epidemiologie MeSH
- incidence MeSH
- juvenilní artritida * farmakoterapie epidemiologie MeSH
- lidé MeSH
- methotrexát terapeutické užití MeSH
- registrace MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVE: To describe risk factors for IBD development in a cohort of children with JIA. METHODS: JIA patients who developed IBD were identified from the international Pharmachild register. Characteristics were compared between IBD and non-IBD patients and predictors of IBD were determined using multivariable logistic regression analysis. Incidence rates of IBD events on different DMARDs were calculated, and differences between therapies were expressed as relative risks (RR). RESULTS: Out of 8942 patients, 48 (0.54% ) developed IBD. These were more often male (47.9% vs 32.0%) and HLA-B27 positive (38.2% vs 21.0%) and older at JIA onset (median 8.94 vs 5.33 years) than patients without IBD development. They also had more often a family history of autoimmune disease (42.6% vs 24.4%) and enthesitis-related arthritis (39.6% vs 10.8%). The strongest predictors of IBD on multivariable analysis were enthesitis-related arthritis [odds ratio (OR): 3.68, 95% CI: 1.41, 9.40] and a family history of autoimmune disease (OR: 2.27, 95% CI: 1.12, 4.54). Compared with methotrexate monotherapy, the incidence of IBD on etanercept monotherapy (RR: 7.69, 95% CI: 1.99, 29.74), etanercept with methotrexate (RR: 5.70, 95% CI: 1.42, 22.77) and infliximab (RR: 7.61, 95% CI: 1.27, 45.57) therapy was significantly higher. Incidence on adalimumab was not significantly different (RR: 1.45, 95% CI: 0.15, 13.89). CONCLUSION: IBD in JIA was associated with enthesitis-related arthritis and a family history of autoimmune disease. An increased IBD incidence was observed for etanercept therapy regardless of concomitant methotrexate use.
Children's Hospital Affiliate of Vilnius University Hospital Santaros Clinic
Clinic of Children's Diseases Vilnius University Vilnius Lithuania
Clinica Pediatrica e Reumatologia IRCCS Istituto Giannina Gaslini
Department of Clinical Medicine UiT the Arctic University of Norway Tromso Norway
Department of Medical Physics Alexandru Ioan Cuza University of Iasi Iasi Romania
Department of Paediatrics University of Zagreb School of Medicine Zagreb Croatia
Department of Pediatrics St Olavs University Hospital of Trondheim Trondheim Norway
Department of Pediatrics University Hospital of North Norway
Division of Pediatric Rheumatology Institute of Rheumatology of Belgrade Belgrade Serbia
Pediatric Rheumatology Unit São Paulo State University Botucatu Brasil
Sir Ganga Ram Hospital Marg Centre for Child Health Sir Ganga Ram Hospital New Delhi India
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018466
- 003
- CZ-PrNML
- 005
- 20220804134802.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/rheumatology/keab678 $2 doi
- 035 __
- $a (PubMed)34508559
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a van Straalen, Joeri W $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- 245 10
- $a Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use / $c JW. van Straalen, RM. Krol, G. Giancane, V. Panaviene, LM. Ailioaie, P. Doležalová, M. Cattalini, G. Susic, FR. Sztajnbok, D. Maritsi, T. Constantin, S. Sawhney, M. Rygg, SK. Oliveira, EB. Nordal, C. Saad-Magalhães, N. Rubio-Perez, M. Jelusic, S. de Roock, NM. Wulffraat, N. Ruperto, JF. Swart
- 520 9_
- $a OBJECTIVE: To describe risk factors for IBD development in a cohort of children with JIA. METHODS: JIA patients who developed IBD were identified from the international Pharmachild register. Characteristics were compared between IBD and non-IBD patients and predictors of IBD were determined using multivariable logistic regression analysis. Incidence rates of IBD events on different DMARDs were calculated, and differences between therapies were expressed as relative risks (RR). RESULTS: Out of 8942 patients, 48 (0.54% ) developed IBD. These were more often male (47.9% vs 32.0%) and HLA-B27 positive (38.2% vs 21.0%) and older at JIA onset (median 8.94 vs 5.33 years) than patients without IBD development. They also had more often a family history of autoimmune disease (42.6% vs 24.4%) and enthesitis-related arthritis (39.6% vs 10.8%). The strongest predictors of IBD on multivariable analysis were enthesitis-related arthritis [odds ratio (OR): 3.68, 95% CI: 1.41, 9.40] and a family history of autoimmune disease (OR: 2.27, 95% CI: 1.12, 4.54). Compared with methotrexate monotherapy, the incidence of IBD on etanercept monotherapy (RR: 7.69, 95% CI: 1.99, 29.74), etanercept with methotrexate (RR: 5.70, 95% CI: 1.42, 22.77) and infliximab (RR: 7.61, 95% CI: 1.27, 45.57) therapy was significantly higher. Incidence on adalimumab was not significantly different (RR: 1.45, 95% CI: 0.15, 13.89). CONCLUSION: IBD in JIA was associated with enthesitis-related arthritis and a family history of autoimmune disease. An increased IBD incidence was observed for etanercept therapy regardless of concomitant methotrexate use.
- 650 12
- $a antirevmatika $x škodlivé účinky $7 D018501
- 650 12
- $a juvenilní artritida $x farmakoterapie $x epidemiologie $7 D001171
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a etanercept $x škodlivé účinky $7 D000068800
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 12
- $a idiopatické střevní záněty $x farmakoterapie $x epidemiologie $7 D015212
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a methotrexát $x terapeutické užití $7 D008727
- 650 _2
- $a registrace $7 D012042
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Krol, Roline M $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- 700 1_
- $a Giancane, Gabriella $u Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini $u Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Università degli Studi di Genova, Genoa, Italy
- 700 1_
- $a Panaviene, Violeta $u Children's Hospital, Affiliate of Vilnius University Hospital Santaros Clinic $u Clinic of Children's Diseases, Vilnius University, Vilnius, Lithuania
- 700 1_
- $a Ailioaie, Laura Marinela $u Department of Medical Physics, Alexandru Ioan Cuza University of Iasi, Iasi, Romania
- 700 1_
- $a Doležalová, Pavla $u Department of Pediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Cattalini, Marco $u Unita' di Immunologia e Reumatologia Pediatrica, Clinica Pediatrica dell'Universita' di Brescia, Spedali Civili, Brescia, Italy
- 700 1_
- $a Susic, Gordana $u Division of Pediatric Rheumatology, Institute of Rheumatology of Belgrade, Belgrade, Serbia
- 700 1_
- $a Sztajnbok, Flavio R $u Unit of Rheumatology, Adolescent Health Studies Center (NESA), Rio de Janeiro State University, Rio de Janeiro, Brazil
- 700 1_
- $a Maritsi, Despoina $u 2nd Department of Pediatrics Athens Medical School, National and Kapodistrian University of Athens (NKUA), Athens, Greece
- 700 1_
- $a Constantin, Tamas $u Unit of Pediatric Rheumatology-Immunology, Second Department of Pediatrics, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Sawhney, Sujata $u Sir Ganga Ram Hospital Marg, Centre for Child Health, Sir Ganga Ram Hospital, New Delhi, India
- 700 1_
- $a Rygg, Marite $u Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology $u Department of Pediatrics, St Olavs University Hospital of Trondheim, Trondheim, Norway
- 700 1_
- $a Oliveira, Sheila Knupp $u Instituto de Puericultura e Pediatria Martagao Gesteira (IPPMG), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
- 700 1_
- $a Nordal, Ellen Berit $u Department of Pediatrics, University Hospital of North Norway $u Department of Clinical Medicine, UiT the Arctic University of Norway, Tromso, Norway
- 700 1_
- $a Saad-Magalhães, Claudia $u Pediatric Rheumatology Unit, São Paulo State University (UNESP), Botucatu, Brasil
- 700 1_
- $a Rubio-Perez, Nadina $u Departamento de Pediatria, Facultad de Medicina, Hospital Universitario "Dr. J. E. González", Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
- 700 1_
- $a Jelusic, Marija $u Department of Paediatrics, University of Zagreb School of Medicine, Zagreb, Croatia
- 700 1_
- $a de Roock, Sytze $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- 700 1_
- $a Wulffraat, Nico M $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- 700 1_
- $a Ruperto, Nicolino $u Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini $1 https://orcid.org/0000000184077782
- 700 1_
- $a Swart, Joost F $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands $1 https://orcid.org/0000000227592822
- 773 0_
- $w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 61, č. 5 (2022), s. 2104-2112
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34508559 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134755 $b ABA008
- 999 __
- $a ok $b bmc $g 1822175 $s 1169709
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 61 $c 5 $d 2104-2112 $e 20220505 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
- LZP __
- $a Pubmed-20220720
